Robert F. Williamson III is Director at Perspective Therapeutics, Inc. (CATX). They have made 11 open-market trades across 2 companies since 2011, most recently 2025-11-12.
CIK 0001397331
10 open-market purchases totalling $626K since 2023, against 1 sale. Across 10 scored buys the stock is up 87.4% at ninety days, and 82.3 points ahead of the S&P over the same stretch.
10 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| CATX | 9,864 | $21K |
| VRUS | 7,000 | — |
| Total | $21K |
Shares reported on the most recent Form 4, priced at the 2025-11-14 close. 1 holding could not be priced and is excluded from the total.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 70% | 80% |
| Avg Move | +4.8% | +11.7% | +87.4% |
| Alpha | +3.9% | +9.1% | +82.3% |
| Scored | 10 | 10 | 10 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CATX | BUY | 2025-11-12 | 2025-11-14 | $2.10 | $20K | +5.7% | +20.4% | +137.9% |
| CATX | BUY | 2025-03-28 | 2025-04-01 | $2.19 | $264K | -4.4% | +21.1% | +68.6% |
| CATX | BUY | 2024-11-25 | 2024-11-27 | $3.64 | $23K | -12.0% | -23.1% | -35.9% |
| CATX | BUY | 2024-05-31 | 2024-06-03 | $1.38 | $76K | -20.5% | -26.4% | -2.9% |
| CATX | BUY | 2024-05-29 | 2024-05-30 | $1.33 | $40K | -9.4% | -19.4% | +9.7% |
| CATX | BUY | 2024-01-30 | 2024-02-01 | $0.71 | $91K | -2.0% | +28.8% | +106.6% |
| CATX | BUY | 2024-01-26 | 2024-01-30 | $0.58 | $78K | +16.9% | +16.9% | +113.0% |
| CATX | BUY | 2024-01-24 | 2024-01-26 | $0.49 | $25K | +39.1% | +38.5% | +146.2% |
| CATX | BUY | 2023-12-21 | 2023-12-26 | $0.33 | $1K | +22.9% | +7.1% | +162.5% |
| CATX | BUY | 2023-12-18 | 2023-12-19 | $0.29 | $7K | +11.4% | +52.8% | +168.1% |
| VRUS | SELL | 2011-05-06 | 2011-05-10 | $104.36 | $3.3M | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.